Dysthymia is often characterized by chronic depression. Symptoms of dysthymia are the same as for depression and usually not as severe as major depression. Key symptom of dysthymia is daily depressed mood for at least two years. Another symptom of dysthymia include lowered energy, appetite and sleep disturbances and low self-esteem. Dysthymia does not tend to weaken sufferers to perform all their daily routines, although the disorder is severe enough to cause distress and interference with important life relationships, roles and responsibilities. It changes thinking, feelings, and behavior and physical well-being capabilities of the sufferer.
In recent time, improving healthcare infrastructure and rising number of dysthymia cases are some of the major drivers of the global dysthymia clinical trial market. 
In 2018, the global Dysthymia Clinical Trial market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Dysthymia Clinical Trial status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Dysthymia Clinical Trial development in United States, Europe and China.

The key players covered in this study
Sanofi
Auckland UniServices
Columbia Northwest Pharmaceuticals
New York State Psychiatric Institute
University Of Washington
Centre For Addiction And Mental Health
University Hospital Freiburg
University Of Barcelona
St.Luke’S-Roosevelt Hospital Center
Sheba Medical Center
University Of California
Oregon Health & Science University
Sunnybrook Health Sciences Centre

Market segment by Type, the product can be split into
Drugs
Others

Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Dysthymia Clinical Trial status, future forecast, growth opportunity, key market and key players.
To present the Dysthymia Clinical Trial development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Dysthymia Clinical Trial are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.